anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous research has suggested that the monocyte-to-high-density lipoprotein ratio (MHR), an emerging inflammatory biomarker, holds promise in predicting the prevalence of various cardiovascular and metabolic diseases. However, earlier investigations were constrained by the relatively modest sample sizes. This study endeavored to expand the sample size and conduct a more comprehensive exploration of the potential relationship between MHR and hyperuricemia. This cross-sectional study incorporated data from participants of the 2009 to 2018 National Health and Nutrition Examination Survey (NHANES) with complete and qualifying information. MHR was determined by calculating the ratio between monocyte count and high-density lipoprotein levels. Various statistical methodologies such as weighted multivariate logistic regression, subgroup analysis, smoothed curve fitting, and threshold analysis, have been used to explore the correlation between hyperuricemia and MHR. The study included a cohort of 17,694 participants, of whom 3512 were diagnosed with hyperuricemia. MHR levels were notably higher in the hyperuricemia group than in the normal group, aligning with an elevated body mass index (BMI). A comprehensive multivariate logistic analysis, accounting for all relevant adjustments, revealed a notable positive correlation between MHR and hyperuricemia (P < .001, OR = 1.98, 95% CI: 1.54-2.54). Subgroup analysis indicated that the MHR exhibited an enhanced predictive capacity for identifying hyperuricemia risk, particularly in females (P < .05). Curvilinear and threshold analyses revealed a nonlinear association between MHR and hyperuricemia prevalence, with a notable inflection point at 0.826. In the US population, a clear positive correlation was observed between the MHR and prevalence of hyperuricemia. Importantly, the MHR is a more robust predictor of hyperuricemia risk in females. Further investigations are required to confirm these findings.
Mounting evidence progressively appreciates the vital interplay between immunity and metabolism in a wide array of immunometabolic chronic disorders, both autoimmune and non-autoimmune mediated. The immune system regulates the functioning of cellular metabolism within organs like the brain, pancreas and/or adipose tissue by sensing and adapting to fluctuations in the microenvironment's nutrients, thereby reshaping metabolic pathways that greatly impact a pro- or anti-inflammatory immunophenotype. While it is agreed that the immune system relies on an adequate nutritional status to function properly, we are only just starting to understand how the supply of single or combined nutrients, all of them termed immunonutrients, can steer immune cells towards a less inflamed, tolerogenic immunophenotype. Polyphenols, a class of secondary metabolites abundant in Mediterranean foods, are pharmacologically active natural products with outstanding immunomodulatory actions. Upon binding to a range of receptors highly expressed in immune cells (e.g. AhR, RAR, RLR), they act in immunometabolic pathways through a mitochondria-centered multi-modal approach. First, polyphenols activate nutrient sensing via stress-response pathways, essential for immune responses. Second, they regulate mammalian target of rapamycin (mTOR)/AMP-activated protein kinase (AMPK) balance in immune cells and are well-tolerated caloric restriction mimetics. Third, polyphenols interfere with the assembly of NLR family pyrin domain containing 3 (NLRP3) in endoplasmic reticulum-mitochondria contact sites, inhibiting its activation while improving mitochondrial biogenesis and autophagosome-lysosome fusion. Finally, polyphenols impact chromatin remodeling and coordinates both epigenetic and metabolic reprogramming. This work moves beyond the well-documented antioxidant properties of polyphenols, offering new insights into the multifaceted nature of these compounds. It proposes a mechanistical appraisal on the regulatory pathways through which polyphenols modulate the immune response, thereby alleviating chronic low-grade inflammation. Furthermore, it draws parallels between pharmacological interventions and polyphenol-based immunonutrition in their modes of immunomodulation across a wide spectrum of socioeconomically impactful immunometabolic diseases such as Multiple Sclerosis, Diabetes (type 1 and 2) or even Alzheimer's disease. Lastly, it discusses the existing challenges that thwart the translation of polyphenols-based immunonutritional interventions into long-term clinical studies. Overcoming these limitations will undoubtedly pave the way for improving precision nutrition protocols and provide personalized guidance on tailored polyphenol-based immunonutrition plans.
INTRODUCTION: An increasing number of breast cancer patients undergo breast-conserving surgery (BCS), but multiple ipsilateral breast cancer (MIBC) is still considered a relative contraindication for breast conservation. This study provides an update on trends in the surgical management for MIBC over a 10-year period.
METHODS: Nationwide data from the Netherlands Cancer Registration of all patients diagnosed with breast cancer between 2011 and 2021 were analysed. The primary outcomes of this study were the incidence of MIBC and the trend in breast surgery type among patients between 2011 and 2021. Secondary outcomes were the positive resection margin rates in patients treated with BCS, the proportion of patients requiring re-excision and overall survival.
RESULTS: In total, 114 433 patients (83%) with unifocal breast cancer and 23 932 patients (17%) with MIBC were identified. The incidence of MIBC was stable (17%) over the years. Overall BCS rates, both primary and after neoadjuvant chemotherapy, increased in MIBC from 29% in 2011 to 41% in 2021. Re-excision was performed in 1348 patients (n = 8455, 16%). The 5-year OS estimate for patients with MIBC treated with BCS was 93%. The pathological complete response (pCR) in MIBC patients treated with neoadjuvant chemotherapy followed by mastectomy was 23%.
CONCLUSION: The breast conservation rate in MIBC has increased over the last decade. In addition, 23% of MIBC patients treated with neoadjuvant chemotherapy followed by mastectomy achieved a pCR. This suggests increasing opportunities for even more BCS in MIBC.
The invention belongs to the technical field of food industry biology, and relates to an issatchenkia terricola acetaldehyde dehydrogenase gene and an expression vector thereof. The sequence of the gene is SEQ ID No. 16, the open reading frame sequence of the gene is SEQ ID No. 17, and the amino acid sequence coded by the gene is SEQ ID No. 18. The gene is inserted into the expression vector to transform escherichia coli for IPTG (isopropyl beta-D-1-thiogalactopyranoside) inducible expression. The expressed recombinant enzyme can catalyze acetaldehyde oxidation to generate acetic acid. The invention provides a novel high-activity acetaldehyde dehydrogenase gene; and the gene realizes recombinant expression in the escherichia coli, overcomes the defect of low yield of acetaldehyde dehydrogenase produced by fermenting the issatchenkia terricola XJ-2, can provide a large amount of acetaldehyde dehydrogenase for researching alcohol relieving products, and lays a foundation for constructing safe acetaldehyde dehydrogenase gene engineering bacteria.
OBJECTIVE: To explore the relationship between personal characteristics of older adults with multiple chronic conditions (MCCs) and perceived shared decision making (SDM) resp. decisional conflict.
METHODS: In a video-observational study (N = 213) data were collected on personal characteristics. The main outcomes were perceived level of SDM and decisional conflict. The mediating variable was participation in the SDM process. A twostep mixed effect multilinear regression and a mediation analysis were performed to analyze the data.
RESULTS: The mean age of the patients was 77.3 years and 56.3% were female. Health literacy (β.01, p < .001) was significantly associated with participation in the SDM process. Education (β = -2.43, p = .05) and anxiety (β = -.26, p = .058) had a marginally significant direct effect on the patients' perceived level of SDM. Education (β = 12.12, p = .002), health literacy (β = -.70, p = .005) and anxiety (β = 1.19, p = .004) had a significant direct effect on decisional conflict. The effect of health literacy on decisional conflict was mediated by participation in SDM.
CONCLUSION: Health literacy, anxiety and education are associated with decisional conflict. Participation in SDM during consultations plays a mediating role in the relationship between health literacy and decisional conflict.
PRACTICE IMPLICATIONS: Tailoring SDM communication to health literacy levels is important for high quality SDM.
The present invention relates to a tradition Chinese medicine composition for treating puerperal mental disorder, which takes more than 10 Chinese herbal medicines of Chinese gentian, golden thread, silktree albizzia bark, frusta ferri etc. as the raw materials. The present invention has the effects of soothing liver, regulating qi, purging heat and tranquillization. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition to treat puerperal mental disorder. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
PURPOSE:The titled pharmaceutical preparation not retarding the eluation of a drug with maintaining its lubricating properties, obtained by blending stearic acid or its salt with a surface active agent. CONSTITUTION:A solid pharmaceutical preparation obtained by compression molding a drug using a lubricant obtained by adding a surface active agent (e.g., ''stearic acid polyoxy 40 '') to stearic acid or its salt (calcium stearate). Although stearic acid or its salt is widely used as a lubricant, stearic acid and its salt are water repellent. The eluation of a drug is retarded in case of a solid pharmaceutical preparation obtained by compression molding using it, so that the manifestation of the medicinal effect is retarded or reduced. The addition of the surface active agent can provide a lubricant not retarding the eluation of the drug with keeping lubricating properties. The amount of the surface active agent blended in the lubricant is preferably about 2-10wt% under normal conditions.
Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
The immediate-release tablets can be taken as whole, dispersed or crushed tablets by mouth, or as dispersed tablets through a nasogastric or orogastric tube (French size 10 or larger). The suspension may be prepared ahead of time and stored at room temperature for up to 8 hours.

Administration of Dispersed Tablets or Crushed Tablets by Mouth

  1. Place the appropriate number of tablets for the prescribed dose into a suitable container. If desired, the tablets may be crushed. Add the appropriate volume of drinking water (other liquids have not been tested) to make a suspension (see Table 1 below).
  2. Swirl the container gently to keep the particles from settling, and administer the suspension before it settles. The mixture will have a bitter taste.
  3. Rinse the container with 15 mL of drinking water and administer the rinse water.
  4. Repeat Step 3. Visually confirm that no particles are left in the container. If particles remain, repeat Step 3.



Administration of Dispersed Tablets through a Nasogastric (NG) or Orogastric (OG) Tube

  1. Remove the cap (if applicable) and plunger out of a 50 or 60 mL catheter-tip compatible syringe or equivalent. Add two tablets into the syringe body and place the plunger back in the syringe. Only two tablets can be administered via NG or OG tube at a time.
  2. Draw 30 mL of drinking water (other liquids have not been tested) into the syringe and hold the syringe with the tip pointing upward. Pull the plunger further to a higher volume position to have some air space in the syringe. Place the cap back on the syringe (if applicable). Shake the syringe well (careful not to spill the contents) for about 30 to 45 seconds or until the tablets are completely dispersed.
  3. Once the tablets are completely dispersed in the syringe, remove the cap from the syringe again (if applicable) and attach the syringe to the NG or OG tube and administer the dispersion before it settles.
  4. Draw 15 mL of water using the same syringe and flush through the same NG or OG tube.
  5. Repeat Step 4 and make sure no particles are left in the syringe by visual inspection. If particles remain, repeat Step 4.
  6. For doses of 800 mg (four 200 mg tablets) and 1,200 mg (six 200 mg tablets) [see Dosage and Administration (2.2)], repeat Steps 1-5 until prescribed dose is reached. The same syringe, NG or OG tube can be used.
Schistosomiasis infects over 200 million individuals and remains a significant cause of morbidity and mortality in developing countries, despite the availability of effective pharmacologic therapy with praziquantel (PZQ). Researchers propose to conduct a phase I study of the pharmacokinetics (PK) and safety of PZQ for the treatment of Schistosomiasis (S.) japonicum among pregnant and lactating women living in the province of Leyte, The Philippines. In practice, treatment of schistosomiasis is withheld for both pregnant and lactating post partum women in the Philippines as well as other countries endemic for schistosomiasis. Without treatment, these women accrue known morbidities identified among non-pregnant subjects including hepatic fibrosis, under-nutrition, and anemia. The overall aims of this study are to see if there are differences in PZQ PK and safety during pregnancy compared to post partum, to describe the kinetics of breast milk transfer of PZQ and to estimate the dose of PZQ received by a nursing infant whose mother is treated with PZQ. This protocol will enroll 15 pregnant women in early pregnancy (12-16 weeks gestation), 15 pregnant women in late pregnancy (30-36 weeks gestation) and 15 lactating nonpregnant women between 5 and 7 months postpartum. The study population will consist of S. japonicum infected women in study villages or at the Municipal Health Centers. Women must be: age 18 or older, otherwise healthy without disease of any major organ system, without history of seizures, chronic medical problem or any neurologic disorders, without history of severe allergic reaction to PZQ and willing to provide informed consent to participate. The pregnant women must: have a singleton pregnancy, be carrying a fetus without evidence of anomaly by ultrasound. Pregnant subjects will be treated with PZQ in early pregnancy (12-16 weeks gestation) or late pregnancy (30-36 weeks gestation), lactating nonpregnant (5-7 months postpartum inclusive ). A total dose of 60 mg/kg of study medication will be provided in 2 split doses over 3 hours as this has been shown to substantially reduce drug side effects. All subjects will be hospitalized overnight for intensive blood sampling and for monitoring for adverse events. Serial breast milk samples will be collected from lactating women. Plasma and breast milk will be assayed for PZQ concentration. PK parameters in pregnant and postpartum women will be compared and kinetics of praziquantel breast milk transfer and estimation of infant PZQ dose from breast milk will be determined. Safety assessments will be performed on pregnant women and their infants through 1 month postpartum, and on postpartum women through 2 weeks post dosing. This study is linked to Division of Microbiology and Infectious Disease (DMID) protocol 06-0039.
BACKGROUND: Human papillomavirus (HPV) vaccine is the most effective option for primary prevention HPV, a well-known cause of cervical cancer.  The objective of the study was to assess awareness of HPV, the acceptability of its vaccine and factors associated with the acceptability among the adult population in Pakistan.
MATERIALS & METHODS: A cross-sectional survey was conducted among adult population of Pakistan from January 2022 and March 2022. Due to the ongoing COVID-19 pandemic, instead of face-to-face interviews, a self-administered questionnaire was developed and distributed through Google Forms. The questionnaire was available in both English and Urdu languages to cater to a diverse population.
RESULTS: Overall, 313 (65.2 %) study participants had heard about HPV infection, while 297 (61.9%) knew HPV as the cause of genital warts and 256 (53.3 %) knew that HPV can cause any type of cancer, with a higher percentage of awareness among those who were in any health care setting compared to those who were in a non-healthcare setting. Regarding the acceptability to get HPV vaccine, 320 (66.7%) of the study participants were willing to get vaccinated, while only 15(3.1%) of the study population had previously received HPV vaccine. The most important factors associated with HPV vaccine acceptability were younger age of 18-25 years (Prevalence Ratio (PR) =1.60, 95% Confidence Interval (CI) =1.11, 2.32), and 26-35 years (PR= 1.65, 95% CI=1.09, 2.50). HPV vaccine acceptability was also associated with working in a healthcare setting due to better awareness of HPV vaccine (PR= 1.29, 95% CI=1.03, 1.62).
CONCLUSION: It is important to address the knowledge gaps existing in the community about HPV vaccine acceptability and barriers against it for the successful rollout of the HPV vaccination program in Pakistan. Mass awareness campaigns about HPV, HPV vaccine, and cervical cancer are needed to increase the acceptability of HPV vaccine among public at the time of reintroducing HPV vaccine.
The invention belongs to the technical field of biology, and particularly relates to an oncolytic virus vaccine and a drug for treating tumors by combining the oncolytic virus vaccine with immune cells. The invention provides a brand-new oncolytic virus attenuated strain by carrying out site-directed mutagenesis on matrix protein M of VSV wild-type virus, wherein the gene sequence of the matrix protein M is shown as SEQ ID NO 3. The attenuated strain can be independently used as a medicament for treating tumors, and has better safety and cure rate than wild viruses and other known attenuated strains. On the basis of the oncolytic virus attenuated strain, the NY-ESO-1 is inserted into the attenuated strain, and the vaccine applicable to tumor treatment is also provided. The vaccine has high cure rate and high biological safety. On the basis of the vaccine, the vaccine and the TCR-T cell are combined for application, and the invention provides a medicament capable of efficiently treating various tumors; on a lung cancer model of a mouse, the cure rate can reach 95 percent.
The present invention relates to a manufacturing method for a chitosan capillary pipe, which is characterized in that the chitosan powder of which the molecular weight is from 500 thousand to 1 million is added into a 0.5% to 3% acetic acid water solution. After the gas in the solution is escaped, a stainless steel straight wire is immersed into the liquid, and then the steel wire of which the surface is uniformly attached with the chitosan is immersed into a NaOH solution; the stainless steel straight wire is taken out after formation; the formed capillary pipe is placed into distilled water to be soaked for 100 to 200 minutes until the pH value of the distilled water is from 6 to 8; after being taken out from a soaking solution and dried, the capillary pipe is stored in alcohol to be used. The chitosan capillary pipe is used as a slow controlled release administration device for treating human diseases. The present invention has the advantages of simple manufacturing method, convenient operation and easy control. The biological property of good compatibility with the human organism of the chitosan which is a marine organism material is used. The degrading speed is slow, and the disadvantages on the aspects of unsatisfactory treating effect, hemolysis, heat source reaction and permeability of the slow controlled release administration are overcome.
Studies performed with mometasone furoate ointment, 0.1% indicate that it is in the medium range of potency as compared with other topical corticosteroids.

In a study evaluating the effects of mometasone furoate ointment on the HPA axis, 15 grams were applied twice daily for 7 days to 6 adult subjects with psoriasis or atopic dermatitis. The ointment was applied without occlusion to at least 30% of the body surface. The results showed that the drug caused a slight lowering of adrenal corticosteroid secretion [see Warnings and Precautions (5.1)].

Sixty-three pediatric subjects ages 6 to 23 months, with atopic dermatitis, were enrolled in an open-label HPA axis safety study. Mometasone furoate ointment, 0.1% was applied once daily for approximately 3 weeks over a mean body surface area of 39% (range 15%-99%). In approximately 27% of subjects who showed normal adrenal function by Cortrosyn test before starting treatment, adrenal suppression was observed at the end of treatment with mometasone furoate ointment, 0.1%. The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the subjects, demonstrated suppressed HPA axis function in 3 subjects, using these same criteria [see Use in Specific Populations (8.4)].
The invention belongs to the field of traditional Chinese medicine processing, and discloses a soaking device for honeysuckle flower buds. The soaking device comprises a soaking barrel. A set of vertical sleeves are arranged in the soaking barrel. The aperture of inner holes of the sleeves ranges from 5 mm to 5.5 mm. Pressing heads are arranged in the sleeves in a sliding mode. Cutters with upward blades are located below the pressing heads in the sleeves in a sliding mode. The soaking device solves the technical problem that at present, due to the fact that medicinal components in the honeysuckle flower buds can not be fully soaked out when the honeysuckle flower buds are soaked, waste is caused.
The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
Purified Frazzled proteins, including WG67-16, WG67-19 and WA628, and processes for producing them are disclosed. DNA molecules encoding the Frazzled proteins, including WG67-16, WG67-19 and WA628, are also disclosed. The proteins may be used in modulating the binding of Wnt genes to their receptor. They are useful in the modulation of cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs. Also, they are useful in the treatment of various disorders associated with defects in cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs including, for example, haematopoietic, gut, neuronal, muscle, brain, lung, pancreas, liver, spleen, kidney, intestines and/or other tissues and organs. In addition, the proteins may be used for inducing formation, growth, differentiation, proliferation and/or maintenance of haematopoietic, gut, neuronal, brain and muscle tissues and of chondrocytes and/or cartilage tissue, and for other tissue repair, such as pancreatic tissue repair. These proteins are also useful for augmenting the activity of other tissue and organ regenerating and differentiation factors.